Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
Health care stocks were advancing Tuesday afternoon, with the NYSE Health Care Index rising 1.2% and the Health Care Select Sector SPDR Fund (XLV) up 0.9%.
The iShares Biotechnology ETF (IBB) gained 1%.
In corporate news, Baxter International shares tumbled 6% after the company said Tuesday it has agreed to sell its kidney care segment to Carlyle for $3.8 billion.
Elanco Animal Health shares jumped 6% after Chief Executive Jeffrey Simmons disclosed a recent stock purchase.
Apollomics shares popped 7% in recent trading after the company reported "positive" preliminary data from a phase 2 trial of vebreltinib to treat people with non-central nervous system solid tumors.
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 1% on Tuesday.
The Dow traded up 0.42% to 39,522.57 while the NASDAQ rose 1.68% to 17,063.04. The S&P 500 also rose, gaining, 1.02% to 5,399.03.
Leading and Lagging Sectors
Information technology shares climbed by 2.3% on Tuesday.
In trading on Tuesday, energy shares fell 1.2%.
Top Headline
The Home Depot, Inc. reported mixed results for its second quarter on Tuesday.
HD reported second-quarter 2024 sales growth of 0.6% year-over-year to $43.175 billion, marginally missing the consensus estimate of $43.376 billion. Adjusted EPS was $4.67 (-0.2% year over year), beating the consensus of $4.50.
Home Depot raised its sales guidance from $154.20 billion to $156.49 billion – $158.01 billion versus the consensus of $158.88 billion. It expects Comparable sales to decline between 3% and 4% (prior ~1%). HD expects Adjusted EPS of $14.66-$14.96 versus the consensus of $15.14.
Equities Trading UP
Equities Trading DOWN
Commodities
In commodity news, oil traded down 1.6% to $78.79 while gold traded up 0.3% at $2,512.30.
Silver traded down 0.9% to $27.745 on Tuesday, while copper fell 0.6% to $4.0450.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.44%, Germany's DAX rose 0.43% and France's CAC 40 rose 0.26%. Spain's IBEX 35 Index rose 0.75%, while London's FTSE 100 rose 0.21%.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei 225 jumping 3.45%, Hong Kong's Hang Seng Index gaining 0.36%, China's Shanghai Composite Index gaining 0.34% and S&P BSE Sensex falling 0.87%.
Economics
U.S. producer prices rose 0.1% month-over-month in July compared to a 0.2% increase in June and versus market expectations of 0.2%.
Now Read This:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
On Tuesday, Apollomics Inc.‘s stock surged as the company announced preliminary clinical data for the cohort of patients with non-CNS MET fusion solid tumors from the Phase 2 SPARTA trial of vebreltinib.
The SPARTA trial is evaluating the efficacy and safety of vebreltinib in a range of MET-altered tumors.
As of the data analysis cutoff date of July 31, 14 patients with non-CNS MET fusion solid tumors were included in the study.
An objective response rate (ORR) of 43% was observed, including six confirmed responses, out of 14 evaluable patients including one complete response in third-line metastatic NSCLC and five partial responses (three patients with NSCLC, one patient in pancreatic cancer, and one patient with intrahepatic bile duct cancer).
Median overall survival (OS) was 12.4 months, and median progression-free survival was 4.5 months.
The median duration of response is 5.6 months, with a median time to response of 3.7 months. The longest recorded response is 18 months, with the patient still undergoing treatment.
Based on these new data, Apollomics is evaluating opportunities for further development of vebreltinib in patients with MET fusions.
Patients currently enrolled in the SPARTA MET fusion cohort will continue with treatment and study follow-up.
In November 2023, Apollomics’ partner in China, Avistone Biotechnology Co. Ltd., received conditional approval from the National Medical Products Administration (NMPA) of China for the commercialization of vebreltinib to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC).
Price Action: APLM stock is up 15.6% at $0.18 at last check Tuesday.
Read Next:
Image created using artificial intelligence via Midjourney.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 200 points on Tuesday.
The Dow traded up 0.47% to 39,542.44 while the NASDAQ rose 1.24% to 16,989.15. The S&P 500 also rose, gaining, 0.83% to 5,388.59.
Leading and Lagging Sectors
Information technology shares climbed by 1.4% on Tuesday.
In trading on Tuesday, energy shares fell 0.8%.
Top Headline
U.S. producer prices rose 0.1% month-over-month in July compared to a 0.2% increase in June and versus market expectations of 0.2%.
Equities Trading UP
Equities Trading DOWN
Commodities
In commodity news, oil traded down 0.8% to $79.32 while gold traded up 0.2% at $2,509.60.
Silver traded down 1.1% to $27.70 on Tuesday, while copper fell 0.8% to $4.0340.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.2%, Germany's DAX rose 0.2% and France's CAC 40 fell 0.1%. Spain's IBEX 35 Index rose 0.4%, while London's FTSE 100 rose 0.2%.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei 225 jumping 3.45%, Hong Kong's Hang Seng Index gaining 0.36%, China's Shanghai Composite Index gaining 0.34% and S&P BSE Sensex falling 0.87%.
Economics
U.S. producer prices rose 0.1% month-over-month in July compared to a 0.2% increase in June and versus market expectations of 0.2%.
Now Read This: Starbucks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.